Emgality 300 mg: First and only calcitonin gene-related peptide (CGRP) antibody proven to treat patients with episodic cluster headache1,2

For your patients with episodic cluster headache,

Meet Frank, a patient with episodic cluster headache

aHypothetical patient profile.

Emgality 300 mg: Life with fewer episodic cluster headache attacks is possible for patients like Frank1

  • 1 to 4 cluster attacks per day during active periods that last 7 weeks, followed by periods (≥3 months) of remission

Get your eligible patients started. Download savings cardsc.

cGovernmental beneficiaries excluded; terms and conditions apply.

References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0093.

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.